Biotech Values

[mcbio]

Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent

Interesting. So, they are dropping their nuke (GS 9190) from these trials, which also includes one of their PIs (GS 9451 or GS 9256), pegylated interferon, and ribavirin. Yet, they are continuing with the nuke in trials without pegIFN and also continuing trials of one of the PIs (9451) in combo with an NS5A inhibitor, pegIFN, and riba.

So, sounds like they think the nuke has issues combining with pegIFN. Is that your take? How do they know the SAEs aren't attributable to the nuke alone or to their PI, either alone, or in combo with another agent?